http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 10 Jun 2026 08:02:05 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Incannex+receives+A%246+million+R%26D+tax+refund+from+Australia/26627038.html <p>Incannex Healthcare Inc. (NASDAQ: IXHL) received A$6,039,162.43 under the Australian Government's Research and Development Tax Incentive Program, according to a company statement.</p><p>The clinical-stage biopharmaceutical company expects to receive an additional A$5.1 million in future R&D tax incentive proceeds in 2026. The combined proceeds represent more than A$11.1 million in non-dilutive capital.</p><p>The Australian Government's Research and Development Tax Incentive Program provides eligible companies with cash refunds for qualifying research and development activities conducted in Australia. The proceeds are non-dilutive, allowing companies to recover research and development expenditure without issuing additional shares or taking on debt.</p><p>"The receipt of more than A$6 million http://www.streetinsider.com/Corporate+News/Incannex+receives+A%246+million+R%26D+tax+refund+from+Australia/26627038.html Wed, 10 Jun 2026 08:02:05 -0400 IXHL http://www.streetinsider.com/Press+Releases/Incannex+Receives+A%246.0+Million+R%26D+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626851.html <p><strong>In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&amp;D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under the program to more than A$11.1 million received in 2026</strong></p><p align="left">NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program.</p> <p align="left">The Company also expects to receive http://www.streetinsider.com/Press+Releases/Incannex+Receives+A%246.0+Million+R%26D+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626851.html Wed, 10 Jun 2026 08:00:00 -0400 IXHL http://www.streetinsider.com/Globe+Newswire/Incannex+Receives+A%246.0+Million+R%26D+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626851.html <p><strong>In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&amp;D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under the program to more than A$11.1 million received in 2026</strong></p><p align="left">NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program.</p> <p align="left">The Company also expects to receive http://www.streetinsider.com/Globe+Newswire/Incannex+Receives+A%246.0+Million+R%26D+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626851.html Wed, 10 Jun 2026 08:00:00 -0400 IXHL http://www.streetinsider.com/Press+Releases/Incannex+Receives+A%246.0+Million+R%26amp%3BD+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626996.html <p align="left">NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program.</p> <p align="left">The Company also expects to receive an additional approximately A$5.1 million in future R&amp;D Tax Incentive proceeds to be received in 2026. Combined, these proceeds represent more than A$11.1 million in non-dilutive capital that further strengthens the Company&apos;s balance sheet and enhances financial flexibility as http://www.streetinsider.com/Press+Releases/Incannex+Receives+A%246.0+Million+R%26amp%3BD+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626996.html Wed, 10 Jun 2026 08:00:00 -0400 IXHL O.03257153 http://www.streetinsider.com/Press+Releases/Incannex+Receives+A%246.0+Million+R%26amp%3BD+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626996.html <p align="left">NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program.</p> <p align="left">The Company also expects to receive an additional approximately A$5.1 million in future R&amp;D Tax Incentive proceeds to be received in 2026. Combined, these proceeds represent more than A$11.1 million in non-dilutive capital that further strengthens the Company&apos;s balance sheet and enhances financial flexibility as http://www.streetinsider.com/Press+Releases/Incannex+Receives+A%246.0+Million+R%26amp%3BD+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626996.html Wed, 10 Jun 2026 08:00:00 -0400 IXHL O.03257153 http://www.streetinsider.com/Globe+Newswire/Incannex+Receives+A%246.0+Million+R%26amp%3BD+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626996.html <p align="left">NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program.</p> <p align="left">The Company also expects to receive an additional approximately A$5.1 million in future R&amp;D Tax Incentive proceeds to be received in 2026. Combined, these proceeds represent more than A$11.1 million in non-dilutive capital that further strengthens the Company&apos;s balance sheet and enhances financial flexibility as http://www.streetinsider.com/Globe+Newswire/Incannex+Receives+A%246.0+Million+R%26amp%3BD+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626996.html Wed, 10 Jun 2026 08:00:00 -0400 IXHL O.03257153 http://www.streetinsider.com/Globe+Newswire/Incannex+Receives+A%246.0+Million+R%26amp%3BD+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626996.html <p align="left">NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, is pleased to announce that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program.</p> <p align="left">The Company also expects to receive an additional approximately A$5.1 million in future R&amp;D Tax Incentive proceeds to be received in 2026. Combined, these proceeds represent more than A$11.1 million in non-dilutive capital that further strengthens the Company&apos;s balance sheet and enhances financial flexibility as http://www.streetinsider.com/Globe+Newswire/Incannex+Receives+A%246.0+Million+R%26amp%3BD+Tax+Incentive+Refund+for+FY25%2C+Further+Strengthening+Balance+Sheet+and+Financial+Flexibility/26626996.html Wed, 10 Jun 2026 08:00:00 -0400 IXHL O.03257153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Incannex+Healthcare+Inc.++For%3A+Jun+10/26626576.html si-local-file:///var/storage/secattach/20260610/26626576.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Incannex+Healthcare+Inc.++For%3A+Jun+10/26626576.html Wed, 10 Jun 2026 07:31:00 -0400 IXHL O.03257153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Incannex+Healthcare+Inc.++For%3A+Jun+10/26626576.html si-local-file:///var/storage/secattach/20260610/26626576.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Incannex+Healthcare+Inc.++For%3A+Jun+10/26626576.html Wed, 10 Jun 2026 07:31:00 -0400 IXHL O.03257153 http://www.streetinsider.com/Press+Releases/Incannex+Announces+Initiation+of+Research+Coverage+by+Alliance+Global+Partners/26620429.html <p>MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and next-generation medicines for high-impact indications, is pleased to announce that Alliance Global Partners (“AGP”) has initiated equity research coverage of the Company.</p> <p>The research report, authored by AGP Managing Director and Senior Biotechnology Analyst James Molloy, provides an independent assessment of Incannex’s clinical pipeline, development strategy, market opportunities and future growth prospects.</p> <p>Research Coverage Highlights</p> <ul type="disc"><li style="margin-top:10pt; margin-bottom:10pt;">Rating: BUY</li><li style="margin-top:10pt; margin-bottom:10pt;">Price Target: US$18.00 per share</li><li http://www.streetinsider.com/Press+Releases/Incannex+Announces+Initiation+of+Research+Coverage+by+Alliance+Global+Partners/26620429.html Tue, 09 Jun 2026 08:00:00 -0400 IXHL http://www.streetinsider.com/Globe+Newswire/Incannex+Announces+Initiation+of+Research+Coverage+by+Alliance+Global+Partners/26620429.html <p>MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and next-generation medicines for high-impact indications, is pleased to announce that Alliance Global Partners (“AGP”) has initiated equity research coverage of the Company.</p> <p>The research report, authored by AGP Managing Director and Senior Biotechnology Analyst James Molloy, provides an independent assessment of Incannex’s clinical pipeline, development strategy, market opportunities and future growth prospects.</p> <p>Research Coverage Highlights</p> <ul type="disc"><li style="margin-top:10pt; margin-bottom:10pt;">Rating: BUY</li><li style="margin-top:10pt; margin-bottom:10pt;">Price Target: US$18.00 per share</li><li http://www.streetinsider.com/Globe+Newswire/Incannex+Announces+Initiation+of+Research+Coverage+by+Alliance+Global+Partners/26620429.html Tue, 09 Jun 2026 08:00:00 -0400 IXHL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Incannex+Healthcare+Inc.++For%3A+Jun+09/26620284.html si-local-file:///var/storage/secattach/20260609/26620284.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Incannex+Healthcare+Inc.++For%3A+Jun+09/26620284.html Tue, 09 Jun 2026 07:31:00 -0400 IXHL O.03257153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Incannex+Healthcare+Inc.++For%3A+Jun+09/26620284.html si-local-file:///var/storage/secattach/20260609/26620284.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Incannex+Healthcare+Inc.++For%3A+Jun+09/26620284.html Tue, 09 Jun 2026 07:31:00 -0400 IXHL O.03257153 http://www.streetinsider.com/New+Coverage/Alliance+Global+Partners+Starts+Icannex+Holdings+%28IXHL%29+at+Buy/26614287.html <p>Alliance Global Partners analyst James Molloy initiates coverage on Icannex Holdings (NASDAQ: IXHL) with a Buy rating and a price target of $18.00.</p> <p>For an analyst ratings summary and ratings history on Icannex Holdings <a href="http://www.streetinsider.com/rating_history.php?q=IXHL">click here</a>. For more ratings news on Icannex Holdings <a href="http://www.streetinsider.com/stock_lookup_news.php?q=IXHL&amp;type=analyst">click here</a>.</p> <p>Shares of Icannex Holdings closed at $2.92 yesterday.</p> http://www.streetinsider.com/New+Coverage/Alliance+Global+Partners+Starts+Icannex+Holdings+%28IXHL%29+at+Buy/26614287.html Mon, 08 Jun 2026 07:29:25 -0400 IXHL http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Incannex+Healthcare+Inc.++For%3A+Mar+31/26500763.html si-local-file:///var/storage/secattach/20260515/26500763.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Incannex+Healthcare+Inc.++For%3A+Mar+31/26500763.html Fri, 15 May 2026 09:29:00 -0400 IXHL O.03257153 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Incannex+Healthcare+Inc.++For%3A+Mar+31/26500763.html si-local-file:///var/storage/secattach/20260515/26500763.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Incannex+Healthcare+Inc.++For%3A+Mar+31/26500763.html Fri, 15 May 2026 09:29:00 -0400 IXHL O.03257153 http://www.streetinsider.com/Corporate+News/Incannex+Healthcare+begins+sleep+apnea+drug+trial/26491910.html <p>Incannex Healthcare Inc. (NASDAQ: IXHL) announced it has commenced its DReAMzz clinical study evaluating IHL-42X for obstructive sleep apnea treatment.</p><p>The company completed site feasibility assessments and identified 14 clinical trial sites for the study. Incannex has finished manufacturing IHL-42X drug product, secured import and export permits, and onboarded a distribution partner for site activation and patient dosing.</p><p>The DReAMzz study is designed as a crossover dose optimization study to refine IHL-42X dosing and strengthen the Phase III development program design. The study will evaluate relationships between dose optimization, sleep metrics, and patient-reported outcomes.</p><p>IHL-42X previously received Fast Track designation from the U.S. http://www.streetinsider.com/Corporate+News/Incannex+Healthcare+begins+sleep+apnea+drug+trial/26491910.html Thu, 14 May 2026 10:35:44 -0400 IXHL http://www.streetinsider.com/Press+Releases/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html <p align="left">MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA).</p> <p align="left">The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing of IHL-42X drug product, secured http://www.streetinsider.com/Press+Releases/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html Thu, 14 May 2026 10:35:00 -0400 A.06822034 IXHL O.03257153 O.20026344 http://www.streetinsider.com/Press+Releases/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html <p align="left">MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA).</p> <p align="left">The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing of IHL-42X drug product, secured http://www.streetinsider.com/Press+Releases/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html Thu, 14 May 2026 10:35:00 -0400 A.06822034 IXHL O.03257153 O.20026344 http://www.streetinsider.com/Press+Releases/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html <p align="left">MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA).</p> <p align="left">The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing of IHL-42X drug product, secured http://www.streetinsider.com/Press+Releases/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html Thu, 14 May 2026 10:35:00 -0400 A.06822034 IXHL O.03257153 O.20026344 http://www.streetinsider.com/Press+Releases/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html <p align="left">MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA).</p> <p align="left">The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing of IHL-42X drug product, secured http://www.streetinsider.com/Press+Releases/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html Thu, 14 May 2026 10:35:00 -0400 A.06822034 IXHL O.03257153 O.20026344 http://www.streetinsider.com/Globe+Newswire/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html <p align="left">MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA).</p> <p align="left">The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing of IHL-42X drug product, secured http://www.streetinsider.com/Globe+Newswire/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html Thu, 14 May 2026 10:35:00 -0400 A.06822034 IXHL O.03257153 O.20026344 http://www.streetinsider.com/Globe+Newswire/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html <p align="left">MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA).</p> <p align="left">The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing of IHL-42X drug product, secured http://www.streetinsider.com/Globe+Newswire/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html Thu, 14 May 2026 10:35:00 -0400 A.06822034 IXHL O.03257153 O.20026344 http://www.streetinsider.com/Globe+Newswire/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html <p align="left">MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA).</p> <p align="left">The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing of IHL-42X drug product, secured http://www.streetinsider.com/Globe+Newswire/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html Thu, 14 May 2026 10:35:00 -0400 A.06822034 IXHL O.03257153 O.20026344 http://www.streetinsider.com/Globe+Newswire/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html <p align="left">MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA).</p> <p align="left">The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing of IHL-42X drug product, secured http://www.streetinsider.com/Globe+Newswire/Incannex+Healthcare+Officially+Commences+DReAMzz+Clinical+Study+for+IHL-42X+in+Obstructive+Sleep+Apnea/26491906.html Thu, 14 May 2026 10:35:00 -0400 A.06822034 IXHL O.03257153 O.20026344